Cell therapy (CAR-T) · Kills target cells, directed at DLL3 · developed by Novartis Pharmaceuticals
DJI136 is an autologous T-lymphocyte preparation genetically engineered to express a chimeric antigen receptor specific for DLL3, a Notch pathway protein overexpressed on various cancer cells. The CAR-T cells recognize and selectively kill DLL3-expressing tumor cells. It is being studied in extensive-stage small cell lung cancer and large cell neuroendocrine carcinoma of the lung.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05680922 | Phase 1 | Small Cell Lung Cancer Extensive Stage | Active not recruiting | LEGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung Cancer Extensive Stage
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →